ATE478669T1 - Zusammenstellungen und methoden zur behandlung der alzheimerschen krankheit, schäden des zentralnervensystems und entzündlichen erkrankungen - Google Patents

Zusammenstellungen und methoden zur behandlung der alzheimerschen krankheit, schäden des zentralnervensystems und entzündlichen erkrankungen

Info

Publication number
ATE478669T1
ATE478669T1 AT99963985T AT99963985T ATE478669T1 AT E478669 T1 ATE478669 T1 AT E478669T1 AT 99963985 T AT99963985 T AT 99963985T AT 99963985 T AT99963985 T AT 99963985T AT E478669 T1 ATE478669 T1 AT E478669T1
Authority
AT
Austria
Prior art keywords
disease
alzheimer
compositions
methods
nervous system
Prior art date
Application number
AT99963985T
Other languages
English (en)
Inventor
Gary Landreth
Colin Combs
Jerry Silver
Michael Fitch
Original Assignee
Univ Case Western Reserve
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22742814&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE478669(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Case Western Reserve filed Critical Univ Case Western Reserve
Application granted granted Critical
Publication of ATE478669T1 publication Critical patent/ATE478669T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
AT99963985T 1998-11-27 1999-11-24 Zusammenstellungen und methoden zur behandlung der alzheimerschen krankheit, schäden des zentralnervensystems und entzündlichen erkrankungen ATE478669T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/200,700 US6191154B1 (en) 1998-11-27 1998-11-27 Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases
PCT/US1999/027987 WO2000032190A1 (en) 1998-11-27 1999-11-24 Compositions and methods for the treatment of alzheimer's disease, central nervous system injury, and inflammatory diseases

Publications (1)

Publication Number Publication Date
ATE478669T1 true ATE478669T1 (de) 2010-09-15

Family

ID=22742814

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99963985T ATE478669T1 (de) 1998-11-27 1999-11-24 Zusammenstellungen und methoden zur behandlung der alzheimerschen krankheit, schäden des zentralnervensystems und entzündlichen erkrankungen

Country Status (10)

Country Link
US (1) US6191154B1 (de)
EP (1) EP1133294B1 (de)
JP (4) JP4932991B2 (de)
KR (2) KR100520856B1 (de)
AT (1) ATE478669T1 (de)
AU (1) AU765528C (de)
CA (1) CA2352494C (de)
DE (1) DE69942702D1 (de)
IL (1) IL143313A0 (de)
WO (1) WO2000032190A1 (de)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6521425B2 (en) * 1997-03-05 2003-02-18 New England Biolabs, Inc. Screening and use of reagents which block or activate intein splicing utilizing natural or homologous exteins
EP0831883A1 (de) 1995-05-12 1998-04-01 The Rockefeller University Verfahren zur behandlung der alzheimische krankheit durch modulierung von synapsinen
EP1006794B1 (de) * 1997-03-12 2007-11-28 Robert W. Esmond Verfahren zur behandlung oder prävention der alzheimerischen krankheit
US20040058873A1 (en) * 1998-03-12 2004-03-25 Esmond Robert W. Method for treating or preventing Alzheimer's disease
US20070004670A1 (en) * 1998-07-31 2007-01-04 Richard Wurtman Compositions containing citicoline, and methods of use thereof
US8314064B2 (en) 1998-07-31 2012-11-20 Massachusetts Institute Of Technology Uridine administration stimulates membrane production
US8518882B2 (en) * 1998-07-31 2013-08-27 Massachusetts Institute Of Technology Methods and compositions for ameliorating or inhibiting decline in memory or intelligence or improving same
US20050203053A1 (en) * 1999-07-30 2005-09-15 Wurtman Richard J. Uridine administration improves phosphatide synthesis, synaptic transmission and cogntive function
US8143234B2 (en) * 1998-07-31 2012-03-27 Massachusetts Institute Of Technology Uridine administration improves phosphatide synthesis, synaptic transmission and cognitive function
US6191154B1 (en) * 1998-11-27 2001-02-20 Case Western Reserve University Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases
AU2192000A (en) * 1998-12-17 2000-07-03 Mindset Biopharmaceuticals (Usa) Inc. Increasing brain glucose utilization
US20040034067A1 (en) * 1999-04-15 2004-02-19 Macphee Colin Houston Novel method of treatment
EP1210087A2 (de) * 1999-04-29 2002-06-05 City of Hope Pentoxifylline, pioglitazone und metformin sind inhibitoren der bildung der fortgeschrittenen glykosylierungsendprodukte
GB9917405D0 (en) * 1999-07-23 1999-09-22 Univ Dundee Methods of treatment and drug screening methods
US20030195707A1 (en) * 2000-05-25 2003-10-16 Schork Nicholas J Methods of dna marker-based genetic analysis using estimated haplotype frequencies and uses thereof
US20020077775A1 (en) * 2000-05-25 2002-06-20 Schork Nicholas J. Methods of DNA marker-based genetic analysis using estimated haplotype frequencies and uses thereof
GB0030845D0 (en) * 2000-12-18 2001-01-31 Smithkline Beecham Plc Novel treatment
US6613505B2 (en) 2001-04-12 2003-09-02 Bioresource International, Inc. Composition and method for destruction of infetious prion proteins
JP2004538450A (ja) * 2001-06-08 2004-12-24 ゼノン ジェネティクス，インコーポレイテッド 神経系統障害及び生殖器官障害の治療法
EP1407767A4 (de) * 2001-06-18 2007-01-24 Yamada Sachiko Pparg-agonistische medizinische zusammensetzungen
IL160229A0 (en) * 2001-08-10 2004-07-25 Genset Sa Polynucleotides, polypeptides encoded thereby and their use
US20030212138A1 (en) * 2002-01-14 2003-11-13 Pharmacia Corporation Combinations of peroxisome proliferator-activated receptor-alpha agonists and cyclooxygenase-2 selective inhibitors and therapeutic uses therefor
US20030220374A1 (en) * 2002-01-14 2003-11-27 Pharmacia Corporation Compositions and methods of treatment involving peroxisome proliferator-activated receptor-gamma agonists and cyclooxygenase-2 selective inhibitors
FR2836829B1 (fr) * 2002-03-11 2005-11-25 Bio Merieux Utilisation de l-alpha-lysophosphatidylcholine pour obtenir la differenciation de monocytes en cellules dendritiques matures in vitro
JP3678366B2 (ja) 2002-08-09 2005-08-03 大正製薬株式会社 止痒剤
US7737182B2 (en) 2002-08-09 2010-06-15 Taisho Pharmaceutical Co., Ltd. Pharmaceuticals for xerosis
US20050003998A1 (en) * 2002-08-15 2005-01-06 Goran Bertilsson Therapeutic use of selective LXR modulators
US20040122059A1 (en) * 2002-10-01 2004-06-24 The Penn State Research Foundation PPAR-gamma ligands in the treatment of asthma and allergies
US7981915B2 (en) 2003-04-30 2011-07-19 Beth Israel Deaconess Medical Center Methods for modulating PPAR biological activity for the treatment of diseases caused by mutations in the CFTR gene
US20050107387A1 (en) * 2003-05-13 2005-05-19 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a peroxisome proliferator activated receptor agonist for the treatment of ischemic mediated central nervous system disorders
HU0301358D0 (en) 2003-05-14 2003-07-28 Debreceni Egyetem Novel use of ppargamma agonists
JP4556511B2 (ja) * 2004-06-25 2010-10-06 ソニー株式会社 １５ｄ−ＰＧＪ２、及び、１５ｄ−ＰＧＪ２を用いた方法
US8324276B2 (en) 2005-01-24 2012-12-04 Pronova Biopharma Norge As Fatty acid composition for treatment of alzheimer's disease and cognitive dysfunction
US20090054523A1 (en) * 2005-01-24 2009-02-26 Morten Bryhn Use of a Fatty Acid Composition Containing DHA for the Production of a Medical Product or a Food Stuff for the Treatment of Amyloidos-Related Diseases
BRPI0613358A8 (pt) * 2005-07-08 2017-12-26 Dsm Ip Assets Bv ácidos de gordura poli - insaturada para o tratamento da demência e condições relacionadas à pré-demência
EP1940403A2 (de) * 2005-09-22 2008-07-09 SB Pharmco Puerto Rico Inc. Ppar-gamma-agonisten zur verbesserung der kognitiven funktion in apoe4-negativen patienten
WO2008024749A2 (en) * 2006-08-23 2008-02-28 Case Western Reserve University Methods and compositions for treating ischemic stroke
EP2044951A1 (de) * 2007-10-02 2009-04-08 Merz Pharma GmbH & Co. KGaA Die Verwendung von Substanzen zur Behandlung des Verlustes des Augenlichts bei Menschen mit Glaukom und anderer degenerativer Augenerkrankungen
US8722710B2 (en) 2007-09-26 2014-05-13 Deuterx, Llc Deuterium-enriched pioglitazone
BRPI0817387A2 (pt) * 2007-11-02 2015-09-08 Massachusetts Inst Technology métodos de conformidade de suplementação dietária de uridina e uso dos mesmos
US8846315B2 (en) 2008-08-12 2014-09-30 Zinfandel Pharmaceuticals, Inc. Disease risk factors and methods of use
CA2735578C (en) * 2008-08-12 2018-10-23 Zinfandel Pharmaceuticals, Inc. Method of identifying risk factors for alzheimer's disease comprising tomm40 gene variants
US20120010264A1 (en) * 2009-03-26 2012-01-12 Dainippon Sumitomo Pharma Co., Ltd. Novel medicament for treating cognitive impairment
WO2011006157A2 (en) * 2009-07-10 2011-01-13 Case Western Reserve University Rxr agonist compounds and methods
WO2011047091A1 (en) * 2009-10-13 2011-04-21 Martek Biosciences Corporation Methods for treating traumatic brain injury
EA201391017A1 (ru) 2011-01-10 2014-04-30 Зинфандел Фармасьютикалз, Инк. Способы и готовые лекарственные формы для лечения болезни альцгеймера
WO2012100347A1 (en) * 2011-01-24 2012-08-02 Inceptum Research & Therapeutics, Inc. Compositions comprising a prostaglandin for treating neuropsychiatric conditions
KR20130015932A (ko) * 2011-08-05 2013-02-14 연세대학교 산학협력단 저용량의 치아졸리딘다이온을 포함하는 알츠하이머 병 치료용 약학조성물
WO2013058409A1 (en) 2011-10-21 2013-04-25 Takeda Pharmaceutical Company Limited Sustained-release preparation
WO2013106084A1 (en) * 2012-01-09 2013-07-18 Takeda Pharmaceutical Company Limited Methods and drug products for treating alzheimer's disease
US8865747B2 (en) 2012-03-23 2014-10-21 Fundació Institute D'Investigació Biomėdica de Bellvitge (IDIBELL) Pioglitazone for use in the treatment of adrenoleukodystrophy
CN104341408A (zh) * 2013-08-02 2015-02-11 江苏柯菲平医药股份有限公司 一种阿奇沙坦的新晶型及其制备方法
JP6163084B2 (ja) * 2013-11-11 2017-07-12 キリン株式会社 認知症の予防、治療及び／又は認知機能を改善する組成物、及びこれを用いた医薬、食品
AU2014354808A1 (en) 2013-11-26 2016-06-02 University Of North Texas Health Science Center At Fort Worth Personalized medicine approach for treating cognitive loss
EP3094328B1 (de) * 2014-01-15 2020-08-19 Poxel SA Verfahren zur behandlung von neurologischen, stoffwechsel- und anderen erkrankungen mit enantiomerenreinem deuterium-angereicherten pioglitazon
EA202091120A3 (ru) * 2014-04-02 2020-12-30 Минорикс Терапьютикс С.Л. Производные 2,4-тиазолинидона в лечении расстройств центральной нервной системы
JP7040798B2 (ja) 2016-12-01 2022-03-23 ミノリックス セラピューティクス エセ．エレ． 非アルコール性脂肪性肝疾患を処置するための５－［［４－［２－［５－（１－ヒドロキシエチル）ピリジン－２－イル］エトキシ］フェニル］メチル］－１，３－チアゾリジン－２，４－ジオン
GB201805554D0 (en) * 2018-04-04 2018-05-16 Wren Therapeutics Therapy for protein misfolding disease
US11319313B2 (en) 2020-06-30 2022-05-03 Poxel Sa Crystalline forms of deuterium-enriched pioglitazone
US11767317B1 (en) 2020-06-30 2023-09-26 Poxel Sa Methods of synthesizing enantiopure deuterium-enriched pioglitazone
EP4612503A1 (de) * 2022-11-03 2025-09-10 Seq Biomarque, LLC Verfahren zum nachweis von zellfreier dna (cfdna) und verwendungen davon zur diagnose, behandlung und/oder überwachung von morbus alzheimer
CN119868353A (zh) * 2025-01-23 2025-04-25 兰州大学 曲格列酮在制备预防或治疗神经退行性疾病药物中的应用

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5522636A (en) 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
JPS5697277A (en) 1980-01-07 1981-08-05 Takeda Chem Ind Ltd Thiazolidine derivative
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
JPS58118577A (ja) 1982-01-07 1983-07-14 Takeda Chem Ind Ltd チアゾリジン誘導体
JPS6051189A (ja) 1983-08-30 1985-03-22 Sankyo Co Ltd チアゾリジン誘導体およびその製造法
CN1003445B (zh) 1984-10-03 1989-03-01 武田药品工业株式会社 噻唑烷二酮衍生物，其制备方法和用途
AR240698A1 (es) 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4965188A (en) 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
HU210339B (en) 1985-05-21 1995-03-28 Pfizer Process for preparing thiazolidinediones and their pharmaceutical compositions haring hypoglycemic effect
US4873255A (en) 1987-02-04 1989-10-10 Sankyo Company Limited Thiazolidinone derivatives, their preparation and their use
FI91869C (fi) 1987-03-18 1994-08-25 Tanabe Seiyaku Co Menetelmä antidiabeettisena aineena käytettävien bensoksatsolijohdannaisten valmistamiseksi
EP0295828A1 (de) 1987-06-13 1988-12-21 Beecham Group Plc Chemische Verbindungen
US5225441A (en) * 1987-06-18 1993-07-06 Block Drug Company, Inc. Treatment of periodontal disease
EP0842925A1 (de) 1987-09-04 1998-05-20 Beecham Group Plc Substituierte Thiazolidindionderivate
US5194443A (en) 1987-09-04 1993-03-16 Beecham Group P.L.C. Compounds
US5260445A (en) 1987-09-04 1993-11-09 Beecham Group P.L.C. 2,4-thiazolidinediones
US5232925A (en) 1987-09-04 1993-08-03 Beecham Group P.L.C. Compounds
US5223522A (en) 1988-03-08 1993-06-29 Pfizer Inc. Thiazolidinedione hypoglycemic agents
MX15171A (es) 1988-03-08 1993-05-01 Pfizer Derivados de tiazolidinodiona hipoglicemicos
WO1989008650A1 (en) 1988-03-08 1989-09-21 Pfizer Inc. Thiazolidinedione hypoglycemic agents
US5120754A (en) 1988-03-08 1992-06-09 Pfizer Inc. Thiazolidinedione hypoglycemic agents
JP2524217B2 (ja) * 1988-04-18 1996-08-14 マルハ株式会社 脳機能改善組成物、学習能力増強剤、記憶力増強剤、痴呆予防剤または痴呆治療剤
JPH01279827A (ja) * 1988-05-02 1989-11-10 Taiyo Fishery Co Ltd 脳機能改善組成物、学習能力増強剤、記憶力増強剤、痴呆予防剤、痴呆治療剤、または脳機能改善効果を有する機能性食品
US5208250A (en) 1988-05-25 1993-05-04 Warner-Lambert Company Known and selected novel arylmethylenyl derivatives of thiazolidinones, imidazolidinones and oxazolidinones useful as antiallergy agents and anti-inflammatory agents
GB8901778D0 (en) 1989-01-27 1989-03-15 Univ Court Of The University O Manipulatory technique
US4897405A (en) 1989-04-21 1990-01-30 American Home Products Corporation Novel naphthalenylalkyl-3H-1,2,3,5-oxathiadiazole 2-oxides useful as antihyperglycemic agents
GB8919434D0 (en) 1989-08-25 1989-10-11 Beecham Group Plc Novel compounds
WO1991007107A1 (en) 1989-11-13 1991-05-30 Pfizer Inc. Oxazolidinedione hypoglycemic agents
US5143928A (en) 1990-03-27 1992-09-01 Warner-Lambert Company 3,5-di-tertiarybutyl-4-hydroxyphenylmethylene derivatives of 2-substituted thiazolidinones, oxazolidinones, and imidazolidinones as antiinflammatory agents
PT97507B (pt) 1990-04-27 1998-08-31 Orion Yhtymae Oy Processo para apreparacao de novos derivados de catecol farmacologicamente activos
GB9017218D0 (en) 1990-08-06 1990-09-19 Beecham Group Plc Novel compounds
US5192753A (en) * 1991-04-23 1993-03-09 Mcgeer Patrick L Anti-rheumatoid arthritic drugs in the treatment of dementia
US5143929A (en) 1991-05-09 1992-09-01 Warner-Lambert Company 2-substituted thiazolidinone, oxazolidinone, and imidazolidinone derivatives of fenamates as antiinflammatory agents
JPH0543456A (ja) * 1991-08-13 1993-02-23 Sagami Chem Res Center 血小板活性化因子産生阻害剤
US5714470A (en) 1991-08-22 1998-02-03 Merrell Pharmaceuticals, Inc. Orally-active elastase inhibitors
US5270319A (en) 1991-09-09 1993-12-14 Warner-Lambert Company 5-hydroxy-2-pyrimidinylmethylene derivatives useful as antiinflammatory agents
JP3213760B2 (ja) * 1991-10-24 2001-10-02 マルハ株式会社 痴呆疾患の治療または予防の為の組成物と、それを処方物にした抗痴呆薬
ATE155684T1 (de) * 1992-04-28 1997-08-15 Fresenius Ag Verwendung einer omega-3-fettsäuren enthaltenden emulsion zur herstellung eines parenteral zu verabreichenden arzneimittels zur behandlung von entzündlichen erkrankungen
US5326770A (en) * 1992-07-17 1994-07-05 The Du Pont Merck Pharmaceutical Company Monoamine oxidase-B (MAO-B) inhibitory 5-substituted 2,4-thiazolidinediones useful in treating memory disorders of mammals
GB2269992A (en) 1992-08-14 1994-03-02 Rh Ne Poulenc Rorer Limited Powder inhalation formulations
NZ248573A (en) * 1992-09-10 1996-02-27 Lilly Co Eli 5-arylmethyl (and methylidene) thiazolidin-4-one derivatives; their preparation and pharmaceutical compositions
US5543297A (en) 1992-12-22 1996-08-06 Merck Frosst Canada, Inc. Human cyclooxygenase-2 cDNA and assays for evaluating cyclooxygenase-2 activity
CA2164291C (en) * 1993-06-09 2007-10-30 David John Kyle Methods and pharmaceutical compositions useful for treating neurological disorders
US5478852C1 (en) 1993-09-15 2001-03-13 Sankyo Co Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of impaired glucose tolerance in order to prevent or delay the onset of noninsulin-dependent diabetes mellitus
JPH07291867A (ja) * 1994-04-28 1995-11-07 Sagami Chem Res Center 神経成長因子産生促進剤
JPH07143862A (ja) * 1994-05-06 1995-06-06 Maruha Corp 脳機能改善効果を有する機能性食品。
JPH07309773A (ja) * 1994-05-16 1995-11-28 Sagami Chem Res Center アセチルコリン放出促進剤
US5607967A (en) * 1994-10-27 1997-03-04 Merck & Co., Inc. Treatment of alzheimer's disease with 5-(tetradecyloxy)-2-furan carboxylic acid
JPH08143454A (ja) * 1994-11-17 1996-06-04 Kanagawa Kagaku Kenkyusho:Kk 神経成長因子産生増強剤
US5824692A (en) 1995-01-06 1998-10-20 Lippiello; Patrick Michael Pharmaceutical compositions for prevention and treatment of central nervous system disorders
US6022897A (en) 1995-04-25 2000-02-08 The Salk Institute For Biological Studies Selective modulators of peroxisome proliferator activated receptor-gamma, and methods for the use thereof
GB9509764D0 (en) * 1995-05-15 1995-07-05 Tillotts Pharma Ag Treatment of inflammatory bowel disease using oral dosage forms of omega-3 polyunsaturated acids
DK0859608T3 (da) * 1995-09-18 2004-06-14 Ligand Pharm Inc Behandling af NIDDM med RXR-agonister
US5618835A (en) 1996-02-01 1997-04-08 The Procter & Gamble Company Dihydrobenzofuran and related compounds useful as anti-inflammatory agents
IN182496B (de) 1996-02-20 1999-04-17 Reddy Research Foundation
CA2276288A1 (en) * 1996-12-31 1998-07-09 Laszlo Nagy Treatment of disease states which result from neoplastic cell proliferation using ppar-gamma activators and compositions useful therefor
US5814647A (en) 1997-03-04 1998-09-29 Board Of Regents, The University Of Texas System Use of troglitazone and related compounds for the treatment of the climacteric symptoms
EP1006794B1 (de) * 1997-03-12 2007-11-28 Robert W. Esmond Verfahren zur behandlung oder prävention der alzheimerischen krankheit
WO1999025346A1 (en) 1997-11-19 1999-05-27 Takeda Chemical Industries, Ltd. Novel apoptosis inhibitors
US6191154B1 (en) * 1998-11-27 2001-02-20 Case Western Reserve University Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases
JP2011030253A (ja) * 2010-09-17 2011-02-10 Maspro Denkoh Corp 送信装置

Also Published As

Publication number Publication date
KR100521829B1 (en) 2005-10-17
JP5745012B2 (ja) 2015-07-08
DE69942702D1 (de) 2010-10-07
AU2031200A (en) 2000-06-19
WO2000032190A1 (en) 2000-06-08
CA2352494A1 (en) 2000-06-08
AU765528B2 (en) 2003-09-18
KR20010101085A (ko) 2001-11-14
US6191154B1 (en) 2001-02-20
JP2011093941A (ja) 2011-05-12
CA2352494C (en) 2009-11-17
KR20050067240A (ko) 2005-06-30
KR100520856B1 (ko) 2005-10-17
EP1133294A1 (de) 2001-09-19
JP4932991B2 (ja) 2012-05-16
AU765528C (en) 2004-09-30
JP2014058546A (ja) 2014-04-03
EP1133294A4 (de) 2003-01-08
JP5730055B2 (ja) 2015-06-03
IL143313A0 (en) 2002-04-21
JP2002536294A (ja) 2002-10-29
JP2012140443A (ja) 2012-07-26
EP1133294B1 (de) 2010-08-25

Similar Documents

Publication Publication Date Title
ATE478669T1 (de) Zusammenstellungen und methoden zur behandlung der alzheimerschen krankheit, schäden des zentralnervensystems und entzündlichen erkrankungen
ATE492279T1 (de) Bupropinmetaboliten zur behandlung von dementia und anderen zerebrovasckulären erkrankungen
MA27608A1 (fr) Derives d'hydroxyethylamine utilises pour le traitement de la maladie d'alzheimer
DE69111642D1 (de) Gabapentin und dessen Derivate zur Behandlung neurodegenerativer Krankheiten.
EA200201247A1 (ru) Соединения для лечения болезни альцгеймера
NO961326L (no) Inhibitorer av -amyloidproteinproduksjon
ATE481096T1 (de) Verfahren und zusammensetzungen zur behandlung von zns-erkrankungen
ATE202940T1 (de) Mittel und methoden zur behandlung von plaque- krankheiten
DE60122767D1 (de) Indoly-lsulphonyl-verbindungen zur behandlung von störungen des zns
ATE427114T1 (de) Verwendung von hepcidin zur herstellung eines arzneimittels zur behandlung von eisenhomíostase stírungen
ATE396973T1 (de) Benzylether- und benzylamino-beta-sekretase- hemmer zur behandlung von alzheimer-krankheit
ATE297755T1 (de) Verwendung von lactoferrin in der behandlung von beschwerden, die von allergenen verursacht sind
ATE409176T1 (de) 1-phenylalkancarbonsäurederivate zur behandlung neurodegenerativer erkrankungen
AU7096201A (en) Phospholipid derivatives of valproic acid and mixtures thereof
ATE260653T1 (de) Verwendung von naaladase inhibitoren zur behandlung von angstzuständen und gedächtnisstörungen
MX2024015763A (es) Composiciones y metodos para inhibir la expresion de serina proteasa transmembrana 6 (tmprss6)
ATE446285T1 (de) Für die behandlung von alzheimer-krankheit und ähnlichen leiden geeignete 1-alkyl-3- thiosubstituierte indol-2-alkinsäuren
BR0306855A (pt) Método para o tratamento de distúrbios cognitivos
NO20010940L (no) TAN-1057 derivater
DE60018704D1 (de) Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen
TW200510351A (en) Oxazole compounds for the treatment of neurodegenerative disorders
DE60023139D1 (de) Verwendung von il6r- il6 chimären für die behandlung von neurodegenerativen erkankungen
ATE384133T1 (de) Retinolsäure-rezeptor beta-2 und gentherapievektoren für die behandlung von neurologischen erkrankungen
DE60108241D1 (de) Felabamat-derivate zur behandlung von neuropathischem schmerz
DE602004019133D1 (de) Verwendung von 1,2-diazadibenzoäe,hüazulenen zur herstellung von pharmazeutischen formulierungen für die behandlung und prävention von erkrankungen und störungen des zentralen nervensystems

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties